Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study
Antineoplastic Combined Chemotherapy Protocols
Lymphoma, T-Cell, Peripheral
Brentuximab vedotin, administered sequentially with CHOP or in combination with CHP, had a manageable safety profile and exhibited substantial antitumor activity in newly diagnosed patients with CD30(+) PTCL. A randomized phase III trial is under way, comparing BV+CHP with CHOP (clinical trial No. NCT01777152).